Psych Residents on COVID-19 Front Line; LSD in Phase II ADHD Trial

— News and commentary from the psychiatry world

by Kristen Monaco, Staff Writer, �鶹��ý May 13, 2020

Last Updated May 14, 2020

Even are being recruited to care for COVID-19 patients in the hospitals. (STAT)

According to geotagged Twitter data, for COVID-19-related depression and anxiety tweets, followed by Missouri and Louisiana. (MLive)

The European ADHD Guidelines Group released additional guidance on in patients during the pandemic who haven't had an in-person baseline cardiovascular assessment. (The Lancet Child & Adolescent Health)

Mind Medicine announced it's entering into a phase IIa clinical trial testing in adults with ADHD.

People with schizophrenia who after 12 months of treatment on risperidone (Risperdal) saw an improvement in symptoms along with reductions in weight, metabolic parameters, and prolactin levels. (BMC Psychiatry)

stated that it has been providing alcohol, tobacco, methadone, medical cannabis, and other substances to people suffering from addictions who are quarantined in city-leased hotels. (San Francisco Chronicle)

A meta-analysis determined that use of didn't appear to put a child into any increased risk for autism. (American Journal of Psychiatry)

Arbor Pharmaceuticals announced the FDA accepted a new drug application for the company's -- an immediate-release amphetamine capsule for patients ages 3 and older.

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.